Lexeo Therapeutics, Inc. surges after FDA trial alignment for LX2006 in Friedreich’s ataxia. Click for more on LXEO stock ...
Horikawa had the trained AI read the brain signals of a person watching a new video and predict the most similar meaning ...
Rocket Pharmaceuticals advances gene therapies for rare diseases. Momentum aligns with broader biotech trends in the Nasdaq ...
Lunai Bioworks (NASDAQ: LNAI), an AI-powered drug discovery and biodefense company, has announced a major scientific ...
Fiscal 2026 Guidance Raised -- Revenue outlook increased to $605 million-$620 million for fiscal 2026 (from $590 million-$610 million), and adjusted EBITDA (non-GAAP) to $78 million-$81 million for ...
A Vector Solutions survey of 600 construction supervisors shows most feel responsible for safety and culture but lack ...
The rushed and uneven rollout of A.I. has created a fog in which it is tempting to conclude that there is nothing to see here ...
Lens has established an optics subsidiary in the Hunan capital of Changsha to develop waveguide lenses and premium components directly serving AI glasses and AR display supply chains. In late February ...
Good morning, and thank you for joining us today to discuss our fiscal 2026 first quarter results. On the call with me today ...
Multi-agent collaboration represents a transformational shift from building smarter models to building smarter networks. It’s ...
The signing took place at KFSHRC's pavilion during the Global Health Exhibition 2025, with signatories: Dr. Majid Alfayyadh, ...
AllAfrica on MSN
Encouraging Results From a First-in-Human Phase 1 Clinical Trial of IAVI's Lassa Vaccine Candidate Published in New England Journal of Medicine
One dose elicits robust and long-lasting immune responses in healthy adults in the U.S. and LiberiaKey takeaways: IAVI's Lassa vaccine candidate rVSVΔG-LASV-GPC has an acceptable safety profile and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback